Xbrane Biopharma AB

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

Alvotech has struck a deal worth SEK275m ($27.0m) to acquire Xbrane BioPharma’s R&D operations in Sweden – based in Campus Solna, at the Karolinska Institute outside Stockholm – as well as the fir

The US Food and Drug Administration is increasingly open to approving biosimilar filings without full Phase III clinical trial data. Two recent company disclosures revealed agency scientific advice in

The US Food and Drug Administration is increasingly open to approving biosimilar filings without full Phase III clinical trial data. That is the message conveyed by two recent company disclosures that